Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Human Papillomavirus | Research

Analysis of related factors for pathological upgrading of cervical biopsy from CIN3 to cancer after conical resection

Authors: Zhifang Li, Guiju Zhou, Longfan Jiang, Mengjie Wang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

To investigate related factors for postoperative pathological upgrading of cervical biopsy to cervical cancer (CC) in patients with cervical intraepithelial neoplasia (CIN)3 after conical resection.

Methods

This retrospective study collected data from patients diagnosed with CIN3 by cervical biopsies at the author’s Hospital between January 2012 and December 2022. The primary outcome was the pathological results of patients after conical resection. The pathological findings were categorized into the pathological upgrading group if postoperative pathology indicated CC, while those with normal, inflammatory, or cervical precancerous lesions were classified into the pathological non-upgrading group. The factors associated with upgrading were identified using multivariable logistic regression analysis.

Results

Among 511 patients, there were 125 patients in the pathological upgrading group (24.46%). The patients in the upgrading group were younger (47.68 ± 9.46 vs. 52.11 ± 7.02, P < 0.001), showed a lower proportion of menopausal women (38.40% vs. 53.02%, P = 0.0111), a lower proportion of HSIL (40.00% vs. 57.77%, P = 0.001), a higher rate of HPV-16/18 positive (25.60% vs. 17.36%, P = 0.011), a higher rate of contact bleeding (54.40% vs. 21.50%, P < 0.001), lower HDL levels (1.31 ± 0.29 vs. 1.37 ± 0.34 mmol/L, P = 0.002), higher neutrophil counts (median, 3.50 vs. 3.10 × 109/L, P = 0.001), higher red blood cell counts (4.01 ± 0.43 vs. 3.97 ± 0.47 × 1012/L, P = 0.002), higher platelet counts (204.84 ± 61.24 vs. 187.06 ± 73.66 × 109/L, P = 0.012), and a smaller platelet volume (median, 11.50 vs. 11.90 fL, P = 0.002).The multivariable logistic regression analysis showed that age (OR = 0.90, 95% CI: 0.86–0.94, P < 0.001), menopausal (OR = 2.68, 95% CI: 1.38–5.22, P = 0.004), contact bleeding (OR = 4.80, 95% CI: 2.91–7.91, P < 0.001), and mean platelet volume (OR = 0.83, 95% CI: 0.69–0.99, P = 0.038) were independently associated with pathological upgrading from CIN3 to CC after conical resection.

Conclusion

Age, menopausal, contact bleeding, and mean platelet volume are risk factors of pathological upgrading from CIN3 to CC after conical resection, which could help identify high risk and susceptible patients of pathological upgrading to CC.
Literature
1.
go back to reference Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: one cause, two diseases. Cancer. 2017;123:2219–29.CrossRefPubMed Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: one cause, two diseases. Cancer. 2017;123:2219–29.CrossRefPubMed
2.
go back to reference Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv72–83.CrossRefPubMed Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv72–83.CrossRefPubMed
3.
go back to reference Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
4.
go back to reference NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cervical Cancer. Version 1.2024. Fort Washington: National Comprehensive Cancer Network; 2023. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cervical Cancer. Version 1.2024. Fort Washington: National Comprehensive Cancer Network; 2023.
5.
go back to reference Ahmed Alrajjal,Vaishali Pansare,Moumita Saha Roy Choudhury. Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of Uterine Cervix and Bethesda System. CytoJournal 2021;18(16). Ahmed Alrajjal,Vaishali Pansare,Moumita Saha Roy Choudhury. Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of Uterine Cervix and Bethesda System. CytoJournal 2021;18(16).
7.
go back to reference Gibb RK, Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol. 2011;4:S2–11.PubMedPubMedCentral Gibb RK, Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol. 2011;4:S2–11.PubMedPubMedCentral
8.
go back to reference Wentzensen N, Walker JL, Gold MA, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015;33:83–9.CrossRefPubMed Wentzensen N, Walker JL, Gold MA, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015;33:83–9.CrossRefPubMed
9.
go back to reference Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus guidelines for abnormal cervical Cancer screening tests and Cancer precursors. J Low Genit Tract Dis. 2020;24:102–31.CrossRefPubMedPubMedCentral Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus guidelines for abnormal cervical Cancer screening tests and Cancer precursors. J Low Genit Tract Dis. 2020;24:102–31.CrossRefPubMedPubMedCentral
10.
go back to reference Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121:829–46.CrossRefPubMed Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121:829–46.CrossRefPubMed
11.
go back to reference Jia M, Lan C, Niu J, Liang Y. Risk factors for pathological upgrading in perimenopausal women with cervical intraepithelial neoplasia grade 2/3 following conization. Med (Baltim). 2022;101:e31368.CrossRef Jia M, Lan C, Niu J, Liang Y. Risk factors for pathological upgrading in perimenopausal women with cervical intraepithelial neoplasia grade 2/3 following conization. Med (Baltim). 2022;101:e31368.CrossRef
12.
go back to reference Wang Y, Wang J, Mei H. Diagnosis of cervical intraepithelial neoplasia and invasive cervical carcinoma by cervical biopsy under Colposcopy and analysis of factors influencing. Emerg Med Int. 2022;2022:9621893.CrossRefPubMedPubMedCentral Wang Y, Wang J, Mei H. Diagnosis of cervical intraepithelial neoplasia and invasive cervical carcinoma by cervical biopsy under Colposcopy and analysis of factors influencing. Emerg Med Int. 2022;2022:9621893.CrossRefPubMedPubMedCentral
13.
go back to reference Fan A, Zhang L, Wang C, Wang Y, Han C, Xue F. Analysis of clinical factors correlated with the accuracy of colposcopically directed biopsy. Arch Gynecol Obstet. 2017;296:965–72.CrossRefPubMed Fan A, Zhang L, Wang C, Wang Y, Han C, Xue F. Analysis of clinical factors correlated with the accuracy of colposcopically directed biopsy. Arch Gynecol Obstet. 2017;296:965–72.CrossRefPubMed
14.
go back to reference Fang Y, Gong AY, Haller ST, Dworkin LD, Liu Z, Gong R. The ageing kidney: molecular mechanisms and clinical implications. Ageing Res Rev. 2020;63:101151.CrossRefPubMedPubMedCentral Fang Y, Gong AY, Haller ST, Dworkin LD, Liu Z, Gong R. The ageing kidney: molecular mechanisms and clinical implications. Ageing Res Rev. 2020;63:101151.CrossRefPubMedPubMedCentral
15.
go back to reference Castanon A, Landy R, Cuzick J, Sasieni P. Cervical screening at age 50–64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med. 2014;11:e1001585.CrossRefPubMedPubMedCentral Castanon A, Landy R, Cuzick J, Sasieni P. Cervical screening at age 50–64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med. 2014;11:e1001585.CrossRefPubMedPubMedCentral
17.
go back to reference Giannella L, Fodero C, Boselli F, Mfuta K, Rubino T, Prandi S. Age-related changes in the diagnostic assessment of women with severe cervical lesions. Climacteric. 2015;18:617–23.CrossRefPubMed Giannella L, Fodero C, Boselli F, Mfuta K, Rubino T, Prandi S. Age-related changes in the diagnostic assessment of women with severe cervical lesions. Climacteric. 2015;18:617–23.CrossRefPubMed
18.
go back to reference Giannella L, Giorgi Rossi P, Delli Carpini G, et al. Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3. Gynecol Oncol. 2021;161:741–7.CrossRefPubMed Giannella L, Giorgi Rossi P, Delli Carpini G, et al. Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3. Gynecol Oncol. 2021;161:741–7.CrossRefPubMed
19.
go back to reference Giannella L, Mfuta K, Gardini G, Rubino T, Fodero C, Prandi S. High-grade CIN on cervical biopsy and predictors of the subsequent cone histology results in women undergoing immediate conization. Eur J Obstet Gynecol Reprod Biol. 2015;186:68–74.CrossRefPubMed Giannella L, Mfuta K, Gardini G, Rubino T, Fodero C, Prandi S. High-grade CIN on cervical biopsy and predictors of the subsequent cone histology results in women undergoing immediate conization. Eur J Obstet Gynecol Reprod Biol. 2015;186:68–74.CrossRefPubMed
20.
go back to reference Costa S, Nuzzo MD, Rubino A, et al. Independent determinants of inaccuracy of colposcopically directed punch biopsy of the cervix. Gynecol Oncol. 2003;90:57–63.CrossRefPubMed Costa S, Nuzzo MD, Rubino A, et al. Independent determinants of inaccuracy of colposcopically directed punch biopsy of the cervix. Gynecol Oncol. 2003;90:57–63.CrossRefPubMed
21.
go back to reference Li L, Wu J, Pu D, et al. Factors associated with the age of natural menopause and menopausal symptoms in Chinese women. Maturitas. 2012;73:354–60.CrossRefPubMed Li L, Wu J, Pu D, et al. Factors associated with the age of natural menopause and menopausal symptoms in Chinese women. Maturitas. 2012;73:354–60.CrossRefPubMed
22.
go back to reference Yang D, Haines CJ, Pan P, et al. Menopausal symptoms in mid-life women in southern China. Climacteric. 2008;11:329–36.CrossRefPubMed Yang D, Haines CJ, Pan P, et al. Menopausal symptoms in mid-life women in southern China. Climacteric. 2008;11:329–36.CrossRefPubMed
23.
go back to reference Lan Y, Huang Y, Song Y, et al. Prevalence, severity, and associated factors of menopausal symptoms in middle-aged Chinese women: a community-based cross-sectional study in southeast China. Menopause. 2017;24:1200–7.CrossRefPubMed Lan Y, Huang Y, Song Y, et al. Prevalence, severity, and associated factors of menopausal symptoms in middle-aged Chinese women: a community-based cross-sectional study in southeast China. Menopause. 2017;24:1200–7.CrossRefPubMed
24.
go back to reference Du L, Xu B, Huang C, Zhu L, He N. Menopausal symptoms and Perimenopausal Healthcare-seeking behavior in women aged 40–60 years: A Community-based cross-sectional survey in Shanghai, China. Int J Environ Res Public Health. 2020;17. Du L, Xu B, Huang C, Zhu L, He N. Menopausal symptoms and Perimenopausal Healthcare-seeking behavior in women aged 40–60 years: A Community-based cross-sectional survey in Shanghai, China. Int J Environ Res Public Health. 2020;17.
26.
go back to reference Patibandla JR, Fehniger JE, Levine DA, Jelinic P. Small cell cancers of the female genital tract: Molecular and clinical aspects. Gynecol Oncol. 2018;149:420–7.CrossRefPubMed Patibandla JR, Fehniger JE, Levine DA, Jelinic P. Small cell cancers of the female genital tract: Molecular and clinical aspects. Gynecol Oncol. 2018;149:420–7.CrossRefPubMed
27.
go back to reference Hutchcraft ML, Miller RW. Bleeding from gynecologic malignancies. Obstet Gynecol Clin North Am. 2022;49:607–22.CrossRefPubMed Hutchcraft ML, Miller RW. Bleeding from gynecologic malignancies. Obstet Gynecol Clin North Am. 2022;49:607–22.CrossRefPubMed
28.
go back to reference Adams T, Denny L. Abnormal vaginal bleeding in women with gynaecological malignancies. Best Pract Res Clin Obstet Gynaecol. 2017;40:134–47.CrossRefPubMed Adams T, Denny L. Abnormal vaginal bleeding in women with gynaecological malignancies. Best Pract Res Clin Obstet Gynaecol. 2017;40:134–47.CrossRefPubMed
29.
go back to reference Shapley M, Jordan J, Croft PR. A systematic review of postcoital bleeding and risk of cervical cancer. Br J Gen Pract. 2006;56:453–60.PubMedPubMedCentral Shapley M, Jordan J, Croft PR. A systematic review of postcoital bleeding and risk of cervical cancer. Br J Gen Pract. 2006;56:453–60.PubMedPubMedCentral
30.
go back to reference Shen WJ, Fu S, Li N, et al. Decreased Mean platelet volume is Associated with Cervical Cancer Development. Asian Pac J Cancer Prev. 2017;18:1769–72.PubMedPubMedCentral Shen WJ, Fu S, Li N, et al. Decreased Mean platelet volume is Associated with Cervical Cancer Development. Asian Pac J Cancer Prev. 2017;18:1769–72.PubMedPubMedCentral
31.
go back to reference Qin S, Chen S, Qin S, Chen H, Hu Z, Li S. Correlation between pretreatment hematologic parameters and cervical Cancer patients undergoing hysterectomy: a retrospective study. Clin Lab. 2020;66. Qin S, Chen S, Qin S, Chen H, Hu Z, Li S. Correlation between pretreatment hematologic parameters and cervical Cancer patients undergoing hysterectomy: a retrospective study. Clin Lab. 2020;66.
32.
go back to reference Deng Q, Long Q, Liu Y, Yang Z, Du Y, Chen X. Prognostic value of preoperative peripheral blood mean platelet volume/platelet count ratio (MPV/PC) in patients with resectable cervical cancer. BMC Cancer. 2021;21:1282.CrossRefPubMedPubMedCentral Deng Q, Long Q, Liu Y, Yang Z, Du Y, Chen X. Prognostic value of preoperative peripheral blood mean platelet volume/platelet count ratio (MPV/PC) in patients with resectable cervical cancer. BMC Cancer. 2021;21:1282.CrossRefPubMedPubMedCentral
33.
go back to reference Wang JM, Wang Y, Huang YQ, et al. Prognostic values of platelet-Associated indicators in Resectable Cervical Cancer. Dose Response. 2019;17:1559325819874199.PubMedPubMedCentral Wang JM, Wang Y, Huang YQ, et al. Prognostic values of platelet-Associated indicators in Resectable Cervical Cancer. Dose Response. 2019;17:1559325819874199.PubMedPubMedCentral
34.
go back to reference Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237–49.CrossRefPubMed Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237–49.CrossRefPubMed
35.
go back to reference Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin Thromb Hemost. 2014;40:296–305.CrossRefPubMed Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin Thromb Hemost. 2014;40:296–305.CrossRefPubMed
36.
go back to reference Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17:47–58.CrossRefPubMed Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17:47–58.CrossRefPubMed
37.
go back to reference Gu M, Zhai Z, Huang L, et al. Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer. Breast Cancer. 2016;23:752–60.CrossRefPubMed Gu M, Zhai Z, Huang L, et al. Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer. Breast Cancer. 2016;23:752–60.CrossRefPubMed
Metadata
Title
Analysis of related factors for pathological upgrading of cervical biopsy from CIN3 to cancer after conical resection
Authors
Zhifang Li
Guiju Zhou
Longfan Jiang
Mengjie Wang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12186-w

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine